Esha Kazi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Esha Kazi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Abul Kalam Mohammad Moniruzzaman Mollah
Affiliation Department of Biological Sciences, Asian University for Women (AUW), Chattogram, Bangladesh
1 shared publication - Luigina Micolucci
Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Via Tronto 10/a, 60126 Ancona, Italy
1 shared publication - Most Mauluda Akhtar
Science and Math Program, Asian University for Women, Chattogram 4000, Bangladesh
1 shared publication - Sharmim Sultana
Science and Math Program, Asian University for Women, Chattogram 4000, Bangladesh
1 shared publication - Soriful Islam
Division of Reproductive Sciences and Women’s Health Research, Department of Gynecology and Obstetrics, Johns Hopkins Medicine, Baltimore, USA
1 shared publication - Tasmiha Amin
Science and Math Program, Asian University for Women, Chattogram 4000, Bangladesh
1 shared publication
Latest Publications
- Open Access
- 2 November 2023
- Published by MDPI AG in Future Pharmacology
- Vol. 3 (4) , 789-818
Exploring Inflammasome Complex as a Therapeutic Approach in Inflammatory Diseases
Inflammasomes, a group of multiprotein complexes, are essential in regulating inflammation and immune responses. Several inflammasomes, including nucleotide-binding domain leucine-rich repeat-containing protein 1 (NLRP1), NLRP3, NLRP6, NLRP7, NLRP12, interferon-inducible protein 16 (IFI16), NOD-like receptor family CARD domain-containing protein 4 (NLRC4), absent in melanoma 2 (AIM2), and pyrin, have been studied in various inflammatory diseases. Activating inflammasomes leads to the processing and production of proinflammatory cytokines, such as interleukin (IL)-1β and IL-18. The NLRP3 inflammasome is the most extensively studied and well characterized. Consequently, targeting inflammasomes (particularly NLRP3) with several compounds, including small molecule inhibitors and natural compounds, has been studied as a potential therapeutic strategy. This review provides a comprehensive overview of different inflammasomes and their roles in six inflammatory diseases, including multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, atherosclerosis, type 2 diabetes, and obesity. We also discussed different strategies that target inflammasomes to develop effective therapeutics.
- 2 November 2023
- Published by MDPI AG in Future Pharmacology
- Vol. 3 (4) , 789-818
Open AccessExploring Inflammasome Complex as a Therapeutic Approach in Inflammatory Diseases
Inflammasomes, a group of multiprotein complexes, are essential in regulating inflammation and immune responses. Several inflammasomes, including nucleotide-binding domain leucine-rich repeat-containing protein 1 (NLRP1), NLRP3, NLRP6, NLRP7, NLRP12, interferon-inducible protein 16 (IFI16), NOD-like receptor family CARD domain-containing protein 4 (NLRC4), absent in melanoma 2 (AIM2), and pyrin, have been studied in various inflammatory diseases. Activating inflammasomes leads to the processing and production of proinflammatory cytokines, such as interleukin (IL)-1β and IL-18. The NLRP3 inflammasome is the most extensively studied and well characterized. Consequently, targeting inflammasomes (particularly NLRP3) with several compounds, including small molecule inhibitors and natural compounds, has been studied as a potential therapeutic strategy. This review provides a comprehensive overview of different inflammasomes and their roles in six inflammatory diseases, including multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, atherosclerosis, type 2 diabetes, and obesity. We also discussed different strategies that target inflammasomes to develop effective therapeutics.